A clinicopathologic review of lethal nonmelanoma skin cancers in Western Australia

Nolan, Richard; Chan, Madelynn; Heenan, Peter J.

doi:10.1016/j.jaad.2004.08.016

Cited by 38 publications

(30 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Duration of the remission sequela is based on time until death or 5 years for survivors minus duration of the other sequelae. Duration of disseminated disease was based on Nolan et al 8 for lethal keratinocyte skin cancers and on Surveillance, Epidemiology, and End Results 9 analysis of median survival for patients with stage IV melanoma. Prevalence estimates from the estimation strategy were combined with disability weights to yield skin disease morbidity, expressed in YLDs, for each age-sex-country-year group.…”

Section: International Classification Of Diseases Ninthmentioning

confidence: 99%

181 Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013

Aksut¹,

Dellavalle

Naghavi

2017

Journal of Investigative Dermatology

163

232

View full text Add to dashboard Cite

IMPORTANCE Disability secondary to skin conditions is substantial worldwide. The Global Burden of Disease Study 2013 includes estimates of global morbidity and mortality due to skin diseases.OBJECTIVE To measure the burden of skin diseases worldwide.DATA SOURCES For nonfatal estimates, data were found by literature search using PubMed and Google Scholar in English and Spanish for years 1980 through 2013 and by accessing administrative data on hospital inpatient and outpatient episodes. Data for fatal estimates were based on vital registration and verbal autopsy data.STUDY SELECTION Skin disease data were extracted from more than 4000 sources including systematic reviews, surveys, population-based disease registries, hospital inpatient data, outpatient data, cohort studies, and autopsy data. Data metrics included incidence, prevalence, remission, duration, severity, deaths, and mortality risk.DATA EXTRACTION AND SYNTHESIS Data were extracted by age, time period, case definitions, and other study characteristics. Data points were modeled with Bayesian meta-regression to generate estimates of morbidity and mortality metrics for skin diseases. All estimates were made with 95% uncertainty intervals. MAIN OUTCOMES AND MEASURESDisability-adjusted life years (DALYs), years lived with disability, and years of life lost from 15 skin conditions in 188 countries.RESULTS Skin conditions contributed 1.79% to the global burden of disease measured in DALYs from 306 diseases and injuries in 2013. Individual skin diseases varied in size from 0.38% of total burden for dermatitis (atopic, contact, and seborrheic dermatitis), 0.29% for acne vulgaris, 0.19% for psoriasis, 0.19% for urticaria, 0.16% for viral skin diseases, 0.15% for fungal skin diseases, 0.07% for scabies, 0.06% for malignant skin melanoma, 0.05% for pyoderma, 0.04% for cellulitis, 0.03% for keratinocyte carcinoma, 0.03% for decubitus ulcer, and 0.01% for alopecia areata. All other skin and subcutaneous diseases composed 0.12% of total DALYs. CONCLUSIONS AND RELEVANCE Skin and subcutaneous diseases were the 18th leading cause of global DALYs in Global Burden of Disease 2013. Excluding mortality, skin diseases were the fourth leading cause of disability worldwide.

show abstract

Section: International Classification Of Diseases Ninthmentioning

confidence: 99%

181 Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013

Aksut¹,

Dellavalle

Naghavi

2017

Journal of Investigative Dermatology

163

232

View full text Add to dashboard Cite

show abstract

“…1,2 Although early stage cure rates are excellent, in some patients (5-10%) regional metastatic disease develops, lowering the survival rate by 50%. 3 The rate of distant metastatic disease remains low, even in those patients with regional metastases. 3,4 The inability to identify high risk lesions at the time of initial treatment is further aggravated by a lack of consensus on the appropriate management of regional metastases.…”

Section: Introductionmentioning

confidence: 99%

“…3 The rate of distant metastatic disease remains low, even in those patients with regional metastases. 3,4 The inability to identify high risk lesions at the time of initial treatment is further aggravated by a lack of consensus on the appropriate management of regional metastases. Adequate surgical excision of the primary CSCC and an immediate curative lymphadenectomy remain essential in achieving control over disease progression and patient survival.…”

Section: Introductionmentioning

confidence: 99%

Significance of clinical stage, extent of surgery and outcome in cutaneous squamous cell carcinoma of the head and neck

Svetina

Lukšić

2013

International Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

“…4 Although only a minority of cSCC lesions (<5%) metastasize to regional lymph nodes, the absolute number of patients involved worldwide who may experience associated morbidity and mortality is not inconsequential. 5,6 Predicting the risk of developing lymph node metastases from cSCC is difficult, although several unfavorable primary features reportedly increase a patient's risk. 7 Recent evidence from an Australian study suggested that horizontal tumor dimension was not associated strongly with the development of lymph node metastases.…”

mentioning

confidence: 99%

Metastatic cutaneous squamous cell carcinoma of the head and neck

Oddone

Morgan

Palme

et al. 2009

Cancer

119

View full text Add to dashboard Cite

BACKGROUND:The authors propose a prognostic score model using a prospective study of patients with regional metastatic cutaneous squamous cell carcinoma of the head and neck.METHODS:Two‐hundred fifty patients were analyzed using a competing risks model to identify risk factors for survival. A risk score was obtained using the significant coefficients from the regression model, and cutoff points were determined that separated the score into 3 risk groups (low risk, moderate risk, and high risk).RESULTS:At a median follow‐up of 54 months (range, 1.3‐212 months) 70 of 250 patients (28%) developed recurrent disease: Most were regional recurrences (51 of 70 patients; 73%) in the treated lymph node basin. After regional recurrence, a majority (73%) died of disease. The following 4 variables were associated significantly with survival: immunosuppression (hazard ratio [HR], 3.13; 95% confidence interval [CI], 1.39‐7.05), treatment (HR, 0.32; 95% CI, 0.16‐0.66), extranodal spread (HR, 9.92; 95% CI, 1.28‐77.09), and margin status (HR, 1.85; 95% CI, 1.85‐3.369); and those 4 variables (immuosuppression, treatment, extranodal spread, and margin status) were used to calculate the ITEM score. The 5‐year risk of dying from disease for patients with high‐risk (>3.0), moderate‐risk (>2.6‐3.0), and low‐risk (≤2.6) ITEM scores were 56%, 24%, and 6%, respectively. Fifty‐six of 250 patients (22%) died from another cause.CONCLUSIONS:Patients who underwent surgery and received adjuvant radiotherapy had a better outcome compared with patients who underwent surgery alone. Patients who had moderate‐ or high‐risk ITEM scores, usually because of extranodal spread and involved excision margins, had a poor outcome. The authors recommend considering these patients for inclusion in adjuvant chemoradiotherapy trials. Cancer 2009. © 2009 American Cancer Society.

show abstract

A clinicopathologic review of lethal nonmelanoma skin cancers in Western Australia

Cited by 38 publications

References 34 publications

181 Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013

181 Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013

Significance of clinical stage, extent of surgery and outcome in cutaneous squamous cell carcinoma of the head and neck

Metastatic cutaneous squamous cell carcinoma of the head and neck

Contact Info

Product

Resources

About